MON2 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human Burkitt lymphoma B lymphocyte line, providing a physiologically relevant model for loss-of-function studies of MON2. This polyclonal population enables robust investigation of gene function in the context of endosomal trafficking, receptor recycling, and immune receptor signaling. The cells are suitable for a range of applications, including functional genomics, signaling pathway dissection, and phenotypic screening in a lymphocyte background that retains key immunological characteristics.
Raji cells are a widely used human B lymphocyte cell line originating from a Burkitt lymphoma, characterized by robust proliferation and expression of surface markers involved in antigen presentation and B cell receptor (BCR) signaling. They serve as a model for studying B cell biology, lymphomagenesis, and immune signaling mechanisms. The Raji background endows the MON2 knockout with a relevant cellular context for examining membrane trafficking dynamics in immunoglobulin-producing cells, where endosomal sorting critically influences antigen processing and signal transduction.
MON2 encodes an adaptor protein that bridges ARF GTPases, particularly ARF1, to clathrin-coated vesicle machinery at endosomes. It interacts with GGA adaptor proteins (GGA1, GGA2, GGA3), the clathrin heavy chain, and the AP-1 complex, facilitating retrograde transport of cargo from endosomes to the trans-Golgi network. MON2 also participates in receptor recycling pathways, impacting the intracellular trafficking of the transferrin receptor (TfR) and the epidermal growth factor receptor (EGFR). Upstream, MON2 is regulated by ARF1, ARF6, and Rab GTPases (Rab5, Rab11), and is activated downstream of receptor signaling events such as BCR and TfR engagement. The protein localizes to early endosomes marked by EEA1 and coordinates cargo sorting decisions that maintain endosomal?CGolgi communication.
Knockout of MON2 in Raji B lymphocytes disrupts the fine-tuned endosomal trafficking network, leading to altered surface receptor levels and impaired signaling downstream of the BCR and other immunoreceptors. This disruption is expected to affect antigen presentation and antibody production, given the central role of endosomal sorting in MHC class II loading and B cell activation. The model thus offers a platform to investigate how endosomal adaptor dysfunction contributes to B cell malignancies and immune dysregulation, with potential relevance to lymphoma biology and therapeutic targeting of trafficking pathways.
Researchers can employ these polyclonal knockout cells to dissect endosomal trafficking mechanisms in B cells using assays such as transferrin uptake and recycling, immunofluorescence for endosomal markers (e.g., EEA1, Rab5), and flow cytometry to quantify surface receptor expression. Co-immunoprecipitation and proximity ligation can map MON2 interaction partners, while transcriptomic profiling via RNA-seq reveals downstream gene expression changes. The cells are also suitable for drug sensitivity screens targeting endocytic pathways in lymphoma models. For further information or to inquire about custom applications, please contact Ascent Research.
